Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
Authors (first, second and last of 11)

Cancer Chemotherapy and Pharmacology addresses a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels. The primary focus of this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials.
The journal publishes results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy. Cancer Chemotherapy and Pharmacology is essential reading for pharmacologists and oncologists.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
The journal is pleased to announce Dr. Jan Beumer has been named the new Co-Editor-in-Chief of Cancer Chemotherapy and Pharmacology, effective January 1, 2020.